Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.
In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal (GI) Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, highlighted future research efforts in the advanced gastric cancer space. Some of these pieces of research include large, randomized studies that will aim to further explore the role of pembrolizumab (Keytruda) within this patient population.
Obviously, the landscape has changed. We have frontline data with nivolumab [Opdivo], which has established it as the standard in [patients with a] CPS greater than 5 with chemotherapy. We have the [phase 3] KEYNOTE-811 study [NCT03615326], which established pembrolizumab plus chemotherapy plus trastuzumab [Herceptin] upfront in HER2-positive disease. There are 2 large, randomized phase 3 trials which will clarify the role of pembrolizumab a little bit further. There's something called the [phase 3 KEYNOTE-859] study [NCT03675737], which is a large, global study of pembrolizumab upfront with chemotherapy to look at whether there are any subsets in which you get benefit with chemotherapy plus pembrolizumab over chemotherapy alone. That study is still waiting to read out in the next year or so.